BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1652 related articles for article (PubMed ID: 18698038)

  • 21. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling.
    Ouellet V; Provencher DM; Maugard CM; Le Page C; Ren F; Lussier C; Novak J; Ge B; Hudson TJ; Tonin PN; Mes-Masson AM
    Oncogene; 2005 Jul; 24(29):4672-87. PubMed ID: 15940270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
    Yoshihara K; Tsunoda T; Shigemizu D; Fujiwara H; Hatae M; Fujiwara H; Masuzaki H; Katabuchi H; Kawakami Y; Okamoto A; Nogawa T; Matsumura N; Udagawa Y; Saito T; Itamochi H; Takano M; Miyagi E; Sudo T; Ushijima K; Iwase H; Seki H; Terao Y; Enomoto T; Mikami M; Akazawa K; Tsuda H; Moriya T; Tajima A; Inoue I; Tanaka K;
    Clin Cancer Res; 2012 Mar; 18(5):1374-85. PubMed ID: 22241791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.
    Voutilainen KA; Anttila MA; Sillanpää SM; Ropponen KM; Saarikoski SV; Juhola MT; Kosma VM
    J Clin Pathol; 2006 May; 59(5):460-7. PubMed ID: 16461565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.
    Berchuck A; Iversen ES; Lancaster JM; Pittman J; Luo J; Lee P; Murphy S; Dressman HK; Febbo PG; West M; Nevins JR; Marks JR
    Clin Cancer Res; 2005 May; 11(10):3686-96. PubMed ID: 15897565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.
    Berchuck A; Iversen ES; Lancaster JM; Dressman HK; West M; Nevins JR; Marks JR
    Am J Obstet Gynecol; 2004 Apr; 190(4):910-25. PubMed ID: 15118612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression profiling of epithelial ovarian tumours correlated with malignant potential.
    Warrenfeltz S; Pavlik S; Datta S; Kraemer ET; Benigno B; McDonald JF
    Mol Cancer; 2004 Oct; 3():27. PubMed ID: 15471544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
    Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR
    Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
    Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
    Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
    Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
    Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coordinately up-regulated genes in ovarian cancer.
    Hough CD; Cho KR; Zonderman AB; Schwartz DR; Morin PJ
    Cancer Res; 2001 May; 61(10):3869-76. PubMed ID: 11358798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.
    Jazaeri AA; Lu K; Schmandt R; Harris CP; Rao PH; Sotiriou C; Chandramouli GV; Gershenson DM; Liu ET
    Mol Carcinog; 2003 Feb; 36(2):53-9. PubMed ID: 12557260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform.
    Tsuda H; Birrer MJ; Ito YM; Ohashi Y; Lin M; Lee C; Wong WH; Rao PH; Lau CC; Berkowitz RS; Wong KK; Mok SC
    Cancer Genet Cytogenet; 2004 Dec; 155(2):97-107. PubMed ID: 15571795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population-based molecular prognosis of breast cancer by transcriptional profiling.
    Ma Y; Qian Y; Wei L; Abraham J; Shi X; Castranova V; Harner EJ; Flynn DC; Guo L
    Clin Cancer Res; 2007 Apr; 13(7):2014-22. PubMed ID: 17404081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
    Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
    Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer.
    Duncan TJ; Al-Attar A; Rolland P; Harper S; Spendlove I; Durrant LG
    Int J Gynecol Pathol; 2010 Jan; 29(1):8-18. PubMed ID: 19952944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma.
    Torng PL; Lee YC; Huang CY; Ye JH; Lin YS; Chu YW; Huang SC; Cohen P; Wu CW; Lin CT
    Oncogene; 2008 Apr; 27(15):2137-47. PubMed ID: 17952116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
    L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
    Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of gene signatures for invasive colorectal tumor cells.
    Wiese AH; Auer J; Lassmann S; Nährig J; Rosenberg R; Höfler H; Rüger R; Werner M
    Cancer Detect Prev; 2007; 31(4):282-95. PubMed ID: 17936523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening for genes associated with ovarian cancer prognosis.
    Chang XH; Zhang L; Yang R; Feng J; Cheng YX; Cheng HY; Ye X; Fu TY; Cui H
    Chin Med J (Engl); 2009 May; 122(10):1167-72. PubMed ID: 19493465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of mammaglobin B in epithelial ovarian carcinomas.
    Tassi RA; Bignotti E; Rossi E; Falchetti M; Donzelli C; Calza S; Ravaggi A; Bandiera E; Pecorelli S; Santin AD
    Gynecol Oncol; 2007 Jun; 105(3):578-85. PubMed ID: 17343903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 83.